関節リウマチ治療薬の世界市場レポート 2025年

関節リウマチ治療薬の市場規模は、今後数年間で安定した成長が見込まれます。2029年の年間平均成長率（CAGR）は2.3%で666億1,000万米ドルに成長します。予測期間の成長は、個別化医療の動向、新興国市場の成長、パイプライン開拓、併用療法への注力、ヘルスケア支出の増加に起因すると考えられます。予測期間における主な動向としては、生物学的療法の優位性、バイオシミラーの影響、個別化医療の進展、経口療法の成長、早期診断と介入への注力などが挙げられます。

関節炎の有病率の増加は、今後の関節リウマチ治療薬市場の成長を牽引すると予想されます。関節リウマチは自己免疫疾患であり、免疫系が誤って健康な細胞を攻撃し、身体の患部に炎症や痛みを伴う腫れを引き起こす炎症性疾患です。関節リウマチを効果的に治療するために、様々な薬剤や自己管理技術が利用可能であり、疼痛を軽減し、関節の柔軟性を改善し、病気の進行を遅らせるのに役立っています。例えば、2024年2月、米国の政府機関である国立保健統計センターによると、2022年、成人の関節炎と診断された年齢調整有病率は18.9％で、男性（16.1％）より女性（21.5％）の方が多かった。有病率は年齢とともに著しく増加し、18～34歳の成人では3.6％、75歳以上では53.9％でした。その結果、関節炎患者数の増加が関節リウマチ薬市場の成長を促進すると予想されます。

高齢者人口の拡大は、関節リウマチ治療薬市場の成長に大きく貢献すると予想されます。高齢者人口」とは、生産年齢人口（18～64歳）に対する65歳以上の人口を指します。高齢者の関節リウマチ治療には課題と機会があり、JAK阻害剤や標的合成DMARDsなどの新薬は、この層にとってより安全なプロファイルを持つ可能性のある代替選択肢を提供しています。ReliefWebが2022年7月に報告したように、世界の65歳以上の人口は2022年の10％から2050年には16％に増加し、9,400万人に達し、総人口の23％を占めると予測されています。したがって、高齢者人口の増加は関節リウマチ治療薬市場を推進する重要な要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界関節リウマチ治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の関節リウマチ治療薬市場：成長率分析
• 世界の関節リウマチ治療薬市場の実績：規模と成長, 2019-2024
• 世界の関節リウマチ治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界関節リウマチ治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の関節リウマチ治療薬市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非ステロイド性抗炎症薬（NSAID）
• コルチコステロイド
• 疾患修飾性抗リウマチ薬（DMARD）
• 生物学的反応修飾薬（BRM）
• その他の薬物の種類
• 世界の関節リウマチ治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 話題
• その他の投与経路
• 世界の関節リウマチ治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の関節リウマチ治療薬市場非ステロイド性抗炎症薬（NSAID）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• イブプロフェン
• ナプロキセン
• ジクロフェナク
• インドメタシン
• 世界の関節リウマチ治療薬市場、コルチコステロイドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレドニゾン
• メチルプレドニゾロン
• デキサメタゾン
• 世界の関節リウマチ治療薬市場、疾患修飾性抗リウマチ薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• メトトレキサート
• スルファサラジン
• ヒドロキシクロロキン
• レフルノミド
• 世界の関節リウマチ治療薬市場、生物学的反応修飾薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍壊死因子（TNF）阻害剤
• インターロイキン阻害剤
• B細胞阻害剤
• 世界の関節リウマチ治療薬市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヤヌスキナーゼ阻害剤
• その他の新しい治療法

第7章 地域別・国別分析

• 世界の関節リウマチ治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の関節リウマチ治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 関節リウマチ治療薬市場：競合情勢
• 関節リウマチ治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Merck & Co., Inc.
• Johnson & Johnson Inc.
• Bayer AG
• Teva Pharmaceuticals Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Biogen Inc.
• Regeneron Pharmaceuticals Inc.
• Galapagos NV
• Abbott Laboratories
• Takeda Pharmaceutical Company Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 関節リウマチ治療薬市場2029：新たな機会を提供する国
• 関節リウマチ治療薬市場2029：新たな機会を提供するセグメント
• 関節リウマチ治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Rheumatoid arthritis pharmaceuticals encompass medications designed for the management of an autoimmune disorder characterized by symptoms such as inflammation in the vicinity of joint tissues. These drugs aim to mitigate lasting damage to joints and other tissues while impeding the progression of rheumatoid arthritis.

The primary categories of rheumatoid arthritis pharmaceuticals consist of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), biologic response modifiers (BRMs), and other pharmaceutical classifications. NSAIDs, a subset of these drugs, are utilized for alleviating inflammation, fever, and other inflammatory conditions, offering advantages over steroids by minimizing adverse effects. Administration routes include oral, parenteral, topical, and alternative methods. The distribution channels for rheumatoid arthritis drugs encompass hospital pharmacies, retail pharmacies, and online pharmacies..

The rheumatoid arthritis drugs market research report is one of a series of new reports from The Business Research Company that provides rheumatoid arthritis drugs market statistics, including rheumatoid arthritis drugs industry global market size, regional shares, competitors with a rheumatoid arthritis drugs market share, detailed rheumatoid arthritis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the rheumatoid arthritis drugs industry. This rheumatoid arthritis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rheumatoid arthritis drugs market size has grown marginally in recent years. It will grow from$60.3 billion in 2024 to $60.71 billion in 2025 at a compound annual growth rate (CAGR) of 0.7%. The growth in the historic period can be attributed to increasing disease prevalence, healthcare infrastructure growth, awareness and education initiatives, government initiatives and support, strategic collaborations

The rheumatoid arthritis drugs market size is expected to see steady growth in the next few years. It will grow to $66.61 billion in 2029 at a compound annual growth rate (CAGR) of 2.3%. The growth in the forecast period can be attributed to personalized medicine trends, emerging markets growth, pipeline development, focus on combination therapies, increasing healthcare expenditure. Major trends in the forecast period include biological therapies dominance, biosimilars impact, personalized medicine advances, oral therapies growth, focus on early diagnosis and intervention.

The increasing prevalence of arthritis is expected to drive the growth of the rheumatoid arthritis drugs market in the future. Rheumatoid arthritis is an autoimmune and inflammatory condition in which the immune system mistakenly attacks healthy cells, resulting in inflammation and painful swelling in the affected areas of the body. Various drugs and self-management techniques are available to effectively treat rheumatoid arthritis, helping to reduce pain, improve joint flexibility, and slow the progression of the disease. For example, in February 2024, the National Center for Health Statistics, a US-based government agency, reported that in 2022, the age-adjusted prevalence of diagnosed arthritis among adults was 18.9%, with women (21.5%) being more likely to be affected than men (16.1%). The prevalence significantly increased with age, from 3.6% in adults aged 18-34 to 53.9% in those aged 75 and older. Consequently, the rising number of arthritis cases is expected to drive growth in the rheumatoid arthritis drug market.

The expanding elderly population is anticipated to contribute significantly to the growth of the rheumatoid arthritis drugs market. The term "elderly population" denotes individuals aged 65 and above, relative to the working-age population (18 to 64 years old). Managing rheumatoid arthritis in the elderly presents challenges and opportunities, with newer drugs such as JAK inhibitors and targeted synthetic DMARDs offering alternative options with potentially safer profiles for this demographic. As reported by ReliefWeb in July 2022, the global population of individuals aged 65 or older is projected to increase from 10% in 2022 to 16% in 2050, reaching 94 million and comprising 23% of the total population. Hence, the growth of the elderly population is a key factor propelling the rheumatoid arthritis drugs market.

The rheumatoid arthritis drug market is witnessing a notable trend in product innovations, with companies strategically embracing new product launches to maintain and enhance their market positions. One such example is the introduction of Olokizumab by R-Pharm, a Russian high-tech pharmaceutical company, in August 2022. Olokizumab is a humanized monoclonal antibody targeting the cytokine interleukin-6, a key player in the progression of joint destruction in rheumatoid arthritis. This innovative product, similar to TNF (tumor necrosis factor), mitigates inflammatory responses, thereby reducing disease activity in many rheumatoid arthritis patients.

Major players in the rheumatoid arthritis drug market are actively engaged in pioneering solutions, such as subcutaneous injection, to gain a competitive advantage. Subcutaneous injections, also known as sub-q or SQ injections, involve delivering medication just beneath the skin. For instance, Eisai Co Ltd. and Nippon Medac Co Ltd. collaborated to launch the Metoject Subcutaneous Injection Syringe in November 2022. This product represents the first self-administrable prefilled syringe formulation of methotrexate (MTX) for rheumatoid arthritis approved in Japan. The Metoject Subcutaneous Injection Syringe is user-friendly, featuring a thin, 27-gauge needle for a more comfortable injection experience, a clear injection window, and a straightforward plunger mechanism to facilitate easy self-administration.

In October 2023, Amgen Plc, a prominent US-based biotechnology company, completed the acquisition of Horizon Therapeutic Plc for $27.8 billion. This strategic move enhances Amgen's inflammation portfolio by incorporating first-in-class, early-in-lifecycle medicines designed to treat rare inflammatory diseases. Horizon Therapeutic Plc, an Ireland-based biopharmaceutical company, specializes in providing treatments for focal segmental glomerulosclerosis, kidney transplant rejection, and rheumatoid arthritis drugs. This acquisition positions Amgen to strengthen its position in the market through a diversified and expanded product offering.

Major companies operating in the rheumatoid arthritis drugs market include Pfizer Inc., Abbvie Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, F-Hoffmann La Roche AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Merck & Co Inc., Johnson & Johnson Inc., Bayer AG, Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A, Biogen Inc., Regeneron Pharmaceuticals Inc., Galapagos NV, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, UCB S.A., Astellas Pharma Inc., Corbus Pharmaceuticals Holdings Inc., Roche Holding AG, Daiichi Sankyo Company Limited, Mallinckrodt Pharmaceuticals, Gilead Sciences Inc.

North America was the largest region in the rheumatoid arthritis drugs market in 2024. North America is expected to be the fastest-growing region in the global rheumatoid arthritis market report during the forecast period. The regions covered in the rheumatoid arthritis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the rheumatoid arthritis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The rheumatoid arthritis drugs market consists of sales of products such as abatacept, aceclofenac and adalimumab. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rheumatoid Arthritis Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rheumatoid arthritis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rheumatoid arthritis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rheumatoid arthritis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Corticosteroids; Disease-Modifying Antirheumatic Drugs (DMARDs); Biologic Response Modifiers (BRMs); Other Drug Types
• 2) By Route Of Administration: Oral; Parenteral; Topical; Other Route Of Administrations
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Naproxen; Diclofenac; Indomethacin
• 2) By Corticosteroids: Prednisone; Methylprednisolone; Dexamethasone
• 3) By Disease-Modifying Antirheumatic Drugs: Methotrexate; Sulfasalazine; Hydroxychloroquine; Leflunomide
• 4) By Biologic Response Modifiers: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin Inhibitors; B-cell Inhibitors
• 5) By Other Drug Types: Janus Kinase Inhibitors; Other Novel Therapies
• Companies Mentioned: Pfizer Inc.; Abbvie Inc.; Amgen Inc.; Novartis AG; Boehringer Ingelheim International GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rheumatoid Arthritis Drugs Market Characteristics

3. Rheumatoid Arthritis Drugs Market Trends And Strategies

4. Rheumatoid Arthritis Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Rheumatoid Arthritis Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Rheumatoid Arthritis Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Rheumatoid Arthritis Drugs Market Growth Rate Analysis
• 5.4. Global Rheumatoid Arthritis Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Rheumatoid Arthritis Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Rheumatoid Arthritis Drugs Total Addressable Market (TAM)

6. Rheumatoid Arthritis Drugs Market Segmentation

• 6.1. Global Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroids
• Disease-Modifying Antirheumatic Drugs (DMARDs)
• Biologic Response Modifiers (BRMs)
• Other Drug Types
• 6.2. Global Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Topical
• Other Route Of Administrations
• 6.3. Global Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.4. Global Rheumatoid Arthritis Drugs Market, Sub-Segmentation Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ibuprofen
• Naproxen
• Diclofenac
• Indomethacin
• 6.5. Global Rheumatoid Arthritis Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Methylprednisolone
• Dexamethasone
• 6.6. Global Rheumatoid Arthritis Drugs Market, Sub-Segmentation Of Disease-Modifying Antirheumatic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Methotrexate
• Sulfasalazine
• Hydroxychloroquine
• Leflunomide
• 6.7. Global Rheumatoid Arthritis Drugs Market, Sub-Segmentation Of Biologic Response Modifiers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor Necrosis Factor (TNF) Inhibitors
• Interleukin Inhibitors
• B-cell Inhibitors
• 6.8. Global Rheumatoid Arthritis Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Janus Kinase Inhibitors
• Other Novel Therapies

7. Rheumatoid Arthritis Drugs Market Regional And Country Analysis

• 7.1. Global Rheumatoid Arthritis Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Rheumatoid Arthritis Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rheumatoid Arthritis Drugs Market

• 8.1. Asia-Pacific Rheumatoid Arthritis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rheumatoid Arthritis Drugs Market

• 9.1. China Rheumatoid Arthritis Drugs Market Overview
• 9.2. China Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rheumatoid Arthritis Drugs Market

• 10.1. India Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rheumatoid Arthritis Drugs Market

• 11.1. Japan Rheumatoid Arthritis Drugs Market Overview
• 11.2. Japan Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rheumatoid Arthritis Drugs Market

• 12.1. Australia Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rheumatoid Arthritis Drugs Market

• 13.1. Indonesia Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rheumatoid Arthritis Drugs Market

• 14.1. South Korea Rheumatoid Arthritis Drugs Market Overview
• 14.2. South Korea Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rheumatoid Arthritis Drugs Market

• 15.1. Western Europe Rheumatoid Arthritis Drugs Market Overview
• 15.2. Western Europe Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rheumatoid Arthritis Drugs Market

• 16.1. UK Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rheumatoid Arthritis Drugs Market

• 17.1. Germany Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rheumatoid Arthritis Drugs Market

• 18.1. France Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rheumatoid Arthritis Drugs Market

• 19.1. Italy Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rheumatoid Arthritis Drugs Market

• 20.1. Spain Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rheumatoid Arthritis Drugs Market

• 21.1. Eastern Europe Rheumatoid Arthritis Drugs Market Overview
• 21.2. Eastern Europe Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rheumatoid Arthritis Drugs Market

• 22.1. Russia Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rheumatoid Arthritis Drugs Market

• 23.1. North America Rheumatoid Arthritis Drugs Market Overview
• 23.2. North America Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rheumatoid Arthritis Drugs Market

• 24.1. USA Rheumatoid Arthritis Drugs Market Overview
• 24.2. USA Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rheumatoid Arthritis Drugs Market

• 25.1. Canada Rheumatoid Arthritis Drugs Market Overview
• 25.2. Canada Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rheumatoid Arthritis Drugs Market

• 26.1. South America Rheumatoid Arthritis Drugs Market Overview
• 26.2. South America Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rheumatoid Arthritis Drugs Market

• 27.1. Brazil Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rheumatoid Arthritis Drugs Market

• 28.1. Middle East Rheumatoid Arthritis Drugs Market Overview
• 28.2. Middle East Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rheumatoid Arthritis Drugs Market

• 29.1. Africa Rheumatoid Arthritis Drugs Market Overview
• 29.2. Africa Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rheumatoid Arthritis Drugs Market Competitive Landscape And Company Profiles

• 30.1. Rheumatoid Arthritis Drugs Market Competitive Landscape
• 30.2. Rheumatoid Arthritis Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis

31. Rheumatoid Arthritis Drugs Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. F. Hoffmann-La Roche AG
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca PLC
• 31.5. Merck & Co., Inc.
• 31.6. Johnson & Johnson Inc.
• 31.7. Bayer AG
• 31.8. Teva Pharmaceuticals Industries Ltd.
• 31.9. Sun Pharmaceutical Industries Ltd.
• 31.10. Sanofi S.A.
• 31.11. Biogen Inc.
• 31.12. Regeneron Pharmaceuticals Inc.
• 31.13. Galapagos NV
• 31.14. Abbott Laboratories
• 31.15. Takeda Pharmaceutical Company Limited

32. Global Rheumatoid Arthritis Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rheumatoid Arthritis Drugs Market

34. Recent Developments In The Rheumatoid Arthritis Drugs Market

35. Rheumatoid Arthritis Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Rheumatoid Arthritis Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Rheumatoid Arthritis Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Rheumatoid Arthritis Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer